The estimated Net Worth of Daniel J. O'connor is at least $2.27 Milion dollars as of 27 October 2023. Mr. connor owns over 50,012 units of OncoSec Medical Inc stock worth over $95,997 and over the last 12 years he sold ONCS stock worth over $997,648. In addition, he makes $1,176,720 as President, Chief Executive Officer a Director at OncoSec Medical Inc.
Daniel has made over 18 trades of the OncoSec Medical Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 50,012 units of ONCS stock worth $491,118 on 27 October 2023.
The largest trade he's ever made was selling 50,012 units of OncoSec Medical Inc stock on 27 October 2023 worth over $491,118. On average, Daniel trades about 2,005 units every 43 days since 2013. As of 27 October 2023 he still owns at least 342,845 units of OncoSec Medical Inc stock.
You can see the complete history of Mr. connor stock trades at the bottom of the page.
Daniel J. O'Connor J.D. serves as President, Chief Executive Officer, Director of the Company. Mr. O'Connor brings more than 20 years of successful financing and licensing experience to OncoSec's Board of Directors, most recently serving as President and Chief Executive Officer of Advaxis Immunotherapies. His appointment to the Company's Board is effective immediately. Most recently, as President and Chief Executive Officer of Advaxis Immunotherapies, Mr. O'Connor successfully turned around the company, raising more than $250 million in funding and transforming it into a patient-focused, leading cancer immunotherapy company. He was also instrumental in establishing major partnerships with companies that include Amgen Inc., Merck & Co. and Bristol Myers Squibb. In addition, under his leadership, the company advanced four new cancer immunotherapy drug candidates into clinical trials, as well as several PD-1 combination clinical studies with Keytruda® and Opdivo®. Previously, Mr. O'Connor was Senior Vice President for ImClone Systems where he supported the clinical development, launch, and commercialization of ERBITUX®, and the sale of the company to Eli Lilly in 2008. Mr. O'Connor served as General Counsel at PharmaNet (inventive Health) and was part of the senior leadership team that grew the company from a start-up contract research organization into a leader in clinical research. Mr. O'Connor is a 1995 graduate of the Penn State University's Dickinson School of Law in Carlisle, Pennsylvania and currently serves as an Entrepreneur Trusted Advisor to its Dean. He graduated from the United States Marines Corps Officer Candidate School in 1988 and was commissioned as an officer in the U.S. Marines, attaining the rank of Captain while serving in Saudi Arabia during Operation Desert Shield. Mr. O'Connor is currently the Vice Chairman of BioNJ and was a former New Jersey criminal prosecutor.
As the President, Chief Executive Officer a Director of OncoSec Medical Inc, the total compensation of Daniel Connor at OncoSec Medical Inc is $1,176,720. There are no executives at OncoSec Medical Inc getting paid more.
Daniel Connor is 55, he's been the President, Chief Executive Officer a Director of OncoSec Medical Inc since 2018. There are 4 older and 6 younger executives at OncoSec Medical Inc. The oldest executive at OncoSec Medical Inc is Margaret Dalesandro, 73, who is the Independent Chairman of the Board.
Daniel's mailing address filed with the SEC is 24, North Main Street, Pennington, Mercer County, New Jersey, 08534, United States of America.
Over the last 12 years, insiders at OncoSec Medical Inc have traded over $1,474,366 worth of OncoSec Medical Inc stock and bought 9,275,650 units worth $39,853,210 . The most active insiders traders include Grand Pharmaceutical & Heal..., Holdings, Inc. Alpha a Robert Ward. On average, OncoSec Medical Inc executives and independent directors trade stock every 62 days with the average trade being worth of $51,563. The most recent stock trade was executed by Robert J Del Aversano on 9 February 2023, trading 40 units of ONCS stock currently worth $55.
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
OncoSec Medical Inc executives and other stock owners filed with the SEC include: